BioMed Research International

BioMed Research International / 2021 / Article

Review Article | Open Access

Volume 2021 |Article ID 6667047 |

Mohammad Pourfridoni, Seyede Mahsa Abbasnia, Fateme Shafaei, Javad Razaviyan, Reza Heidari-Soureshjani, "Fluid and Electrolyte Disturbances in COVID-19 and Their Complications", BioMed Research International, vol. 2021, Article ID 6667047, 5 pages, 2021.

Fluid and Electrolyte Disturbances in COVID-19 and Their Complications

Academic Editor: Valeria Cavalcanti Rolla
Received12 Nov 2020
Revised11 Mar 2021
Accepted09 Apr 2021
Published14 Apr 2021


The novel coronavirus disease 2019 (COVID-19) is the cause of an acute respiratory illness which has spread around the world. The virus infects the host by binding to the angiotensin-converting enzyme 2 (ACE2) receptors. Due to the presence of ACE2 receptors in the kidneys and gastrointestinal (GI) tract, kidneys and GI tract damage arising from the virus can be seen in patients and can cause acute conditions such as acute kidney injury (AKI) and digestive problems for the patient. One of the complications of kidneys and GI involvement in COVID-19 is fluid and electrolyte disturbances. The most common ones of these disorders are hyponatremia, hypernatremia, hypokalemia, hypocalcemia, hypochloremia, hypervolemia, and hypovolemia, which if left untreated, cause many problems for patients and even increase mortality. Fluid and electrolyte disturbances are more common in hospitalized and intensive care patients. Children are also at greater risk for fluid and electrolyte disturbances complications. Therefore, clinicians should pay special attention to the fluid and electrolyte status of patients. Changes in fluid and electrolyte levels can be a good indicator of disease progression.

1. Introduction

The 2019 novel coronavirus (2019-nCoV), which has caused the spread of a respiratory pandemic, for the first time, was renamed by the Chinese government as the novel coronavirus pneumonia. The World Health Organization (WHO) later named the emerging disease COVID-19 [1]. Since March 6, 2021, over 115 million cases have been reported globally, with more than 2 million deaths [2]. Coronaviruses are a group of nondividing positive-sense RNA viruses that pertain to the class Coronaviridae and are pathogenic in mammals, especially humans [3]. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is known as the seventh type of coronavirus class of human infection [4]. Six other types of human coronavirus can cause diseases such as SARS-CoV and coronavirus Middle East respiratory syndrome (MERS-CoV) with high mortality [5]. The most common symptoms of COVID-19 include fever, dry cough, fatigue, muscle aches, and other symptoms such as shortness of breath, headache, diarrhea, and indigestion [69]. From the onset of symptoms to death from the disease is between 6 and 41 days, and the average is 14 days. This time is shorter than patients under 70, depending on the patient’s age and immune status [6]. So far, there is no comprehensive antiviral treatment or antiviral drug for COVID-19 [10]. Disease control includes therapeutic measures to control symptoms, supportive and protective measures, disruption of the disease transmission chain by quarantining patients, and experience-based therapy [11]. The WHO has announced COVID-19 outbreak an emergency state [12].

Previous studies have shown that in COVID-19, in addition to the respiratory system, the nervous system, cardiovascular system, gastrointestinal (GI) tract, and urogenital system are also affected by the disease and its complications. Because the GI tract and kidneys play an essential role in fluid and electrolyte balance in the body, disturbance can lead to an imbalance of fluid and electrolytes. Impaired fluid and electrolyte balance can be dangerous if left unchecked.

2. Materials and Methods

This study is aimed at investigating the fluid and electrolyte disturbances in COVID-19 patients and the complications that may occur following these disorders in patients. The literature search for this article has been entirely Internet-based. Web of Science, PubMed, Scopus, and Google Scholar databases were used to collect information. List of terms and phrases, including acute kidney injury (AKI), acute renal injury, renal insufficiencies, renal impairment, renal failures, angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2, COVID-19, 2019-nCoV infection, fluid and electrolyte disturbance, water-electrolyte imbalances, was used for a more focused search. There was no restriction on the date, place, type of study, and inclusion/exclusion criteria for reviewing articles. Studies not written in English were withdrawn.

3. Results and Discussion

3.1. How the SARS-CoV-2 Affects the Kidneys and GI Tract

The coronavirus family causes infections via respiratory droplets, contact, etc. [13]. The ACE2 receptor is a receptor that the SARS-CoV-2 uses, like the SARS-CoV, to perform its pathogenicity [14, 15]. Coronavirus S protein is known to inhibit virus entry into cells [1618]. Protein S binds the receptor to the membrane fusion. This protein performs a very crucial function in determining the number of host tropics and transmission capacity. To function, protein S is split into domains S1 and S2, which perform receptor binding and fusion of cell membranes, respectively [18]. SARS-CoV-2 can cause kidney injury by having a direct effect on the kidney tissue, as ACE2 and members of the serine protease family are intensely expressed on podocytes and tubule epithelial cells [19]. Also, virus entry into GI epithelial cells is mediated by the spike protein on the viral coating initiated by the cellular transmembrane serine protease 2 (TMPRSS-2) [20]. Therefore, the involvement of the kidneys and GI tract in COVID-19 is possible.

3.2. Kidney Involvement in COVID-19

The kidneys have a wide range of roles, including urine formation, hormone secretion, blood pressure regulation, acid-base balance, and osmolality regulation, so their normal function is essential [21]. Acute renal impairment due to COVID-19 is not unexpected. As mentioned, coronavirus enters the cell by binding to ACE2 receptors [14, 15]. Due to the high level of these receptors in kidney cells, the kidneys are not immune to coronavirus invasion. The possible mechanisms that cause renal impairment in cases with COVID-19 are rooted in fluid imbalance due to fever or decreased fluid intake in patients [22]. Recent reports indicate that renal impairment is more common in patients with COVID-19 [8, 22, 23]. The cytopathic effects of COVID-19 on podocytes and proximal tubular straight cells could cause AKI in sufferers with COVID-19, especially in patients whose virus is found in their blood sample. Podocytes and proximal tubular straight cells play an essential role in normal renal function by filtering urine, absorbing, and secreting. Podocytes are much more sensitive to viral and bacterial invasions and are at greater risk. Therefore, more consideration should be paid to new surveillance of renal function and urinary management of COVID-19 patients with AKI to avert unintended infections [24]. Kidney disorders in COVID-19 occur as a result of complex factors. It is important to note that AKI is correlated with considerable mortality in sufferers with COVID-19 [22]. Because many electrolyte disorders have significant consequences to help identify the pathophysiological mechanisms underlying COVID-19 and patient management, they can provide new therapeutic opportunities [25]. The kidneys’ involvement with pathogens can disrupt a wide range of body mechanisms and cause many problems such as fluid and electrolyte imbalances. Therefore, monitoring renal function can prevent severe complications in patients involved with COVID-19 and operates an essential role in reducing mortality. A collection of recent studies shows that the most common renal complication in COVID-19 hospitalized patients is electrolyte disorders, especially hyperkalemia [26].

3.3. GI Tract Involvement in COVID-19

Based on retrospective study data, the prevalence of GI symptoms in COVID-19 patients could be between 11.4 and 50% [20]. Although COVID-19 is known to be a respiratory disease, there is ample evidence that it can damage the GI tract and cause GI symptoms. In patients with COVID-19, the SARS-CoV-2 can damage the normal intestinal mucosa and disrupt its normal function, leading to GI symptoms and difficulty absorbing nutrients. SARS-CoV-2 can also impair the digestive system of the normal intestinal flora and lead to various GI symptoms, especially diarrhea [27]. The ileum and colon can become dysfunctional due to SARS-CoV-2 infection, which leads to multiple manifestations of GI in patients. The most common of these symptoms are diarrhea, nausea, vomiting, and abdominal discomfort [28]. Evidence has shown that SARS-CoV-2 infection is associated with changes in the gut microbiota. Clinical studies on COVID-19 have demonstrated that in COVID-19 patients, GI symptoms can precede respiratory symptoms [29]. GI disorders in COVID-19 patients can lead to fluid and electrolyte disturbance [1, 14, 24, 3032].

3.4. Fluid and Electrolyte Disturbance in COVID-19

Impaired renal function leads to fluid and electrolyte disturbances [33]. GI disorders can also lead to fluid and electrolyte imbalances (the most common type is hypokalemia) [34]. Controlling fluid and electrolyte balance involves several processes in which the kidneys and GI tract play an essential role. As a result, damage to them usually disrupts fluids and electrolyte balance [35].

Studies on COVID-19 confirm electrolyte disturbances in patients, including sodium, potassium, chlorine, and calcium imbalances [8, 31]. One of the most common electrolyte disorders is hyponatremia, which occurs with a heightened risk of mortality in hospitalized patients [36]. Some drugs previously used in the United States Food and Drug Administration’s (FDA) treatment protocol for patients with COVID-19, such as chloroquine and hydroxychloroquine, can cause electrolyte imbalance [37]. People with COVID-19, who are taking drugs that inhibit the RAS, reduce the production of aldosterone, and this can cause fluid and electrolytes imbalances in the patient. Mineralocorticoid receptor (MR), which has different types, is expressed in various tissues, including the kidneys, GI tract such as the colon, central nervous system (CNS), and heart, and is known as aldosterone receptor. Activation of MR leads to changes in the concentration of ions (such as sodium and potassium). These changes are necessary to maintain the balance of fluid and electrolytes in the body. Still, due to MR’s presence in the large intestine [3840], if the aldosterone pathway is disrupted, the absorption and secretion of ions in the colon are disrupted, and fluid and electrolyte imbalance occurs. A case-control study showed that hyponatremia, hypokalemia, and hypochloremia, which are electrolyte disturbances, were more common in COVID-19 patients than in controls [41]. Hypokalemia, a complication of COVID-19, can exacerbate acute respiratory distress syndrome (ARDS) and increase the risk of heart injuries in patients [25]. Hypernatremia is very common in patients with acute COVID-19. Patients with hypernatremia have been in intensive care for a more extended period and have a higher risk of death. Therefore, the amount of ions, including sodium and potassium, is a significant indicator in COVID-19 patients [42]. Hypocalcemia is also one of the electrolyte disorders in patients with COVID-19, which can be dangerous if not controlled and can even increase the mortality rate [43]. In some people with SARS-CoV-2 infection, the syndrome of inappropriate antidiuretic hormone secretion (SIADH) has been reported [44], leading to disturbances in fluid and electrolytes.

3.5. Fluid and Electrolyte Disturbance Complications

Proper electrolyte balance is essential for regulating body functions and sustaining health. Even the slightest deviation from average electrolyte concentrations can cause many problems and sometimes carry death risk. Immediate and decisive treatment is required for fluid and electrolyte disturbances [45]. Fluid and electrolyte disturbances are prevalent in patients admitted to the intensive care unit (ICU). Acute cerebral edema is a disastrous complication for patients with hyponatremia [46]. Rhabdomyolysis, seizures, mood swings, and even coma are some of the difficulties of hyponatremia in patients. Rapid correction of hyponatremia or hypernatremia can lead to the demyelinating osmotic syndrome, so physicians should pay special attention to this issue [46, 47]. Hypokalemia is very destructive if left unchecked and affects the cardiovascular function, neurohormonal activation, and other vital organs [48]. The most common complication of hypocalcemia is increased neuromuscular irritability, which is characterized by muscle spasms, tingling in the limbs, and perioral numbness. Also, hypocalcemia can rarely cause reversible cardiomyopathy [49]. One of the serum electrolytes is chloride; the change in its concentration can increase the risk of acute kidney injury, morbidity, and even mortality [50]. Hypovolemia and hypervolemia can occur in patients with body fluid disturbance [51]. Hypovolemia, if not controlled and treated promptly, leads to ischemic injury of the vital organs and organ failure [52]. Hypervolemia is a life-threatening factor (especially in children), regardless of the severity of the disease [53].

4. Conclusions

In COVID-19, the kidneys and GI tract are at risk, and a variety of complications have been reported that are very common [54, 55]. Fluid and electrolyte disturbances are complications of the kidney and GI injuries in COVID-19 patients. Because fluid and electrolyte disturbances can lead to many problems and even death, clinicians should have special supervision over fluid and electrolyte balance in COVID-19 patients, especially in patients under intensive care because the risk of fluid and electrolyte disturbance is higher in them and it can raise mortality rate [42]. Hyponatremia, hypernatremia, hypokalemia, hypocalcemia, hypochloremia, and changes in fluid body volume are the most common fluid and electrolyte disorders in SARS-CoV-2 infection that should be given special attention. If these disorders are observed, definitive and immediate treatment should be started. Since fluid and electrolyte disturbances can be seen in COVID-19, body fluid volume and electrolyte concentrations can be used to measure disease status and disease progression.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.


We want to thank all the physicians and nurses worldwide for their significant and diligent efforts to oppose COVID-19.


  1. J. F.-W. Chan, S. Yuan, K.-H. Kok et al., “A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,” The Lancet, vol. 395, no. 10223, pp. 514–523, 2020. View at: Publisher Site | Google Scholar
  2. “WHO Coronavirus (COVID-19) dashboard | WHO coronavirus disease (COVID-19) dashboard,” March 2021, View at: Google Scholar
  3. A. R. Fehr and S. Perlman, “Coronaviruses: an overview of their replication and pathogenesis,” Methods in Molecular Biology, vol. 1282, pp. 1–23, 2015. View at: Publisher Site | Google Scholar
  4. N. Zhu, D. Zhang, W. Wang et al., “A novel coronavirus from patients with pneumonia in China, 2019,” The New England Journal of Medicine, vol. 382, no. 8, pp. 727–733, 2020. View at: Google Scholar
  5. S. Su, G. Wong, W. Shi et al., “Epidemiology, genetic recombination, and pathogenesis of coronaviruses,” Trends in Microbiology, vol. 24, no. 6, pp. 490–502, 2016. View at: Publisher Site | Google Scholar
  6. W. Wang, J. Tang, and F. Wei, “Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China,” Journal of Medical Virology, vol. 92, no. 4, pp. 441–447, 2020. View at: Publisher Site | Google Scholar
  7. L.-L. Ren, Y.-M. Wang, Z.-Q. Wu et al., “Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study,” Chinese Medical Journal, vol. 133, no. 9, pp. 1015–1024, 2020. View at: Publisher Site | Google Scholar
  8. C. Huang, Y. Wang, X. Li et al., “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China,” The Lancet, vol. 395, no. 10223, pp. 497–506, 2020. View at: Publisher Site | Google Scholar
  9. W. G. Carlos, C. S. Dela Cruz, B. Cao, S. Pasnick, and S. Jamil, “Novel Wuhan (2019-nCoV) coronavirus,” American Journal of Respiratory and Critical Care Medicine, vol. 201, no. 4, pp. P7–P8, 2020. View at: Publisher Site | Google Scholar
  10. “Q&A on coronaviruses (COVID-19),” July 2020, View at: Google Scholar
  11. “How to Protect Yourself & Others,” July 2020, View at: Google Scholar
  12. “Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV),” July 2020, View at: Google Scholar
  13. M. A. Shereen, S. Khan, A. Kazmi, N. Bashir, and R. Siddique, “COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses,” Journal of Advanced Research, vol. 24, pp. 91–98, 2020. View at: Publisher Site | Google Scholar
  14. P. Zhou, X.-L. Yang, X.-G. Wang et al., “A pneumonia outbreak associated with a new coronavirus of probable bat origin,” Nature, vol. 579, no. 7798, pp. 270–273, 2020. View at: Publisher Site | Google Scholar
  15. W. Li, M. J. Moore, N. Vasilieva et al., “Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus,” Nature, vol. 426, no. 6965, pp. 450–454, 2003. View at: Publisher Site | Google Scholar
  16. E. De Wit, N. Van Doremalen, D. Falzarano, and V. J. Munster, “SARS and MERS: recent insights into emerging coronaviruses,” Nature Reviews. Microbiology, vol. 14, no. 8, pp. 523–534, 2016. View at: Publisher Site | Google Scholar
  17. F. He, Y. Deng, and W. Li, “Coronavirus disease 2019: what we know?” Journal of Medical Virology, vol. 92, no. 7, pp. 719–725, 2020. View at: Publisher Site | Google Scholar
  18. Y. He, Y. Zhou, S. Liu et al., “Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine,” Biochemical and Biophysical Research Communications, vol. 324, no. 2, pp. 773–781, 2004. View at: Publisher Site | Google Scholar
  19. W. Lv, M. Wu, Y. Ren et al., “Coronavirus disease 2019: coronaviruses and kidney injury,” The Journal of Urology, vol. 204, no. 5, pp. 918–925, 2020. View at: Publisher Site | Google Scholar
  20. R. H. Hunt, J. E. East, A. Lanas et al., “COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist,” Digestive Diseases, vol. 39, pp. 119–139, 2020. View at: Google Scholar
  21. “Kidney Health and Kidney Disease Basics: causes and questions,” July 2020, View at: Google Scholar
  22. R. Valizadeh, A. Baradaran, A. Mirzazadeh, and L. V. K. S. Bhaskar, “Coronavirus-nephropathy; renal involvement in COVID-19,” Journal of Renal Injury Prevention, vol. 9, no. 2, article e18, 2020. View at: Publisher Site | Google Scholar
  23. J. S. M. Peiris, C. M. Chu, V. C. C. Cheng et al., “Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study,” The Lancet, vol. 361, no. 9371, pp. 1767–1772, 2003. View at: Publisher Site | Google Scholar
  24. Y. Duan, R. Prasad, D. Feng et al., “Bone marrow-derived cells restore functional integrity of the gut epithelial and vascular barriers in a model of diabetes and ACE2 deficiency,” Circulation Research, vol. 125, no. 11, pp. 969–988, 2019. View at: Publisher Site | Google Scholar
  25. G. Lippi, A. M. South, and B. M. Henry, “Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19),” Annals of Clinical Biochemistry, vol. 57, no. 3, pp. 262–265, 2020. View at: Publisher Site | Google Scholar
  26. S. K. Kunutsor and J. A. Laukkanen, “Renal complications in COVID-19: a systematic review and meta-analysis,” Annals of Medicine, vol. 52, no. 7, pp. 345–353, 2020. View at: Publisher Site | Google Scholar
  27. E. J. T. Aguila, I. H. Y. Cua, J. A. C. Fontanilla, V. L. M. Yabut, and M. F. P. Causing, “Gastrointestinal manifestations of COVID-19: impact on nutrition practices,” Nutrition in Clinical Practice, vol. 35, no. 5, pp. 800–805, 2020. View at: Publisher Site | Google Scholar
  28. M. H. Cha, M. Regueiro, and D. S. Sandhu, “Gastrointestinal and hepatic manifestations of COVID-19: a comprehensive review,” World Journal of Gastroenterology, vol. 26, no. 19, pp. 2323–2331, 2020. View at: Publisher Site | Google Scholar
  29. F. Trottein and H. Sokol, “Potential causes and consequences of gastrointestinal disorders during a SARS-CoV-2 infection,” Cell Reports, vol. 32, no. 3, p. 107915, 2020. View at: Publisher Site | Google Scholar
  30. T. Hashimoto, T. Perlot, A. Rehman et al., “ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation,” Nature, vol. 487, no. 7408, pp. 477–481, 2012. View at: Publisher Site | Google Scholar
  31. W. Guan, Z. Ni, Y. Hu et al., “Clinical characteristics of coronavirus disease 2019 in China,” The New England Journal of Medicine, vol. 382, no. 18, pp. 1708–1720, 2020. View at: Publisher Site | Google Scholar
  32. X.-w. Pan, D. Xu, H. Zhang, W. Zhou, L.-h. Wang, and X.-g. Cui, “Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis,” Intensive Care Medicine, vol. 46, no. 6, pp. 1114–1116, 2020. View at: Publisher Site | Google Scholar
  33. R. Hashem and C. Weissman, “Renal dysfunction and fluid and electrolyte disturbances,” Current Opinion in Critical Care, vol. 17, no. 4, pp. 390–395, 2011. View at: Publisher Site | Google Scholar
  34. A. J. Viera and N. Wouk, “Potassium disorders: hypokalemia and hyperkalemia,” American Family Physician, vol. 92, no. 6, pp. 487–495, 2015. View at: Google Scholar
  35. A. H. Chowdhury and D. N. Lobo, “Fluids and gastrointestinal function,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 14, no. 5, pp. 469–476, 2011. View at: Publisher Site | Google Scholar
  36. G. Corona, C. Giuliani, G. Parenti et al., “Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis,” PLoS One, vol. 8, no. 12, p. e80451, 2013. View at: Publisher Site | Google Scholar
  37. M. A. Chary, A. F. Barbuto, S. Izadmehr, B. D. Hayes, and M. M. Burns, “COVID-19: therapeutics and their toxicities,” Journal of Medical Toxicology, vol. 16, no. 3, pp. 284–294, 2020. View at: Publisher Site | Google Scholar
  38. Z. Belden, J. A. Deiuliis, M. Dobre, and S. Rajagopalan, “The role of the mineralocorticoid receptor in inflammation: focus on kidney and vasculature,” American Journal of Nephrology, vol. 46, no. 4, pp. 298–314, 2017. View at: Publisher Site | Google Scholar
  39. Y.-S. Fan, R. L. Eddy, M. G. Byers et al., “The human mineralocorticoid receptor gene (MLR) is located on chromosome 4 at q31. 2,” Cytogenetic and Genome Research, vol. 52, no. 1–2, pp. 83-84, 1989. View at: Publisher Site | Google Scholar
  40. P. J. Fuller and M. J. Young, “Mechanisms of mineralocorticoid action,” Hypertension, vol. 46, no. 6, pp. 1227–1235, 2005. View at: Publisher Site | Google Scholar
  41. H. De Carvalho, M. C. Richard, T. Chouihed et al., “Electrolyte imbalance in COVID-19 patients admitted to the emergency department: a case-control study,” Internal and Emergency Medicine, vol. 23, pp. 1–6, 2021. View at: Publisher Site | Google Scholar
  42. M. A. Zimmer, A. K. Zink, C. W. Weißer et al., “Hypernatremia—a manifestation of COVID-19: a case series,” A&a Practice, vol. 14, no. 9, p. e01295, 2020. View at: Publisher Site | Google Scholar
  43. A. Raesi, E. S. Dezaki, H. Moosapour et al., “Hypocalcemia in Covid-19: a prognostic marker for severe disease,” Iranian Journal of Pathology, vol. 16, no. 2, pp. 144–153, 2020. View at: Publisher Site | Google Scholar
  44. H. Mabillard and J. A. Sayer, “Electrolyte disturbances in SARS-CoV-2 infection,” F1000Research, vol. 9, p. 587, 2020. View at: Publisher Site | Google Scholar
  45. A. H. Crawford, “Hyperkalemia: recognition and management of a critical electrolyte disturbance,” Journal of Infusion Nursing, vol. 37, no. 3, pp. 167–175, 2014. View at: Publisher Site | Google Scholar
  46. J. W. Lee, “Fluid and electrolyte disturbances in critically ill patients,” Electrolyte & Blood Pressure, vol. 8, no. 2, pp. 72–81, 2010. View at: Publisher Site | Google Scholar
  47. H. Rondon and M. Badireddy, “Hyponatremia,” in StatPearls, StatPearls Publishing, Treasure Island (FL), 2021. View at: Google Scholar
  48. D. Chen, X. Li, Q. Song et al., “Assessment of hypokalemia and clinical characteristics in patients with coronavirus disease 2019 in Wenzhou, China,” JAMA Network Open, vol. 3, no. 6, article e2011122, 2020. View at: Publisher Site | Google Scholar
  49. E. Bove-Fenderson and M. Mannstadt, “Hypocalcemic disorders,” Best Practice & Research. Clinical Endocrinology & Metabolism, vol. 32, no. 5, pp. 639–656, 2018. View at: Publisher Site | Google Scholar
  50. R. K. Thekkeveedu, S. Ramarao, N. Dankhara, and P. Alur, “Hypochloremia secondary to diuretics in preterm infants: should clinicians pay close attention?” Global Pediatric Health, vol. 8, p. 2333794X2199101, 2021. View at: Publisher Site | Google Scholar
  51. M. M. Braun and M. Mahowald, “Electrolytes: sodium disorders,” FP Essentials, vol. 459, pp. 11–20, 2017. View at: Google Scholar
  52. S. Taghavi and R. Askari, “Hypovolemic shock,” in StatPearls, StatPearls Publishing, Treasure Island (FL), 2021. View at: Google Scholar
  53. M. Kopač, “Evaluation of hypervolemia in children,” Journal of Pediatric Intensive Care, vol. 10, no. 1, 2021. View at: Publisher Site | Google Scholar
  54. S. S. Farouk, E. Fiaccadori, P. Cravedi, and K. N. Campbell, “COVID-19 and the kidney: what we think we know so far and what we don’t,” Journal of Nephrology, vol. 33, no. 6, pp. 1213–1218, 2020. View at: Publisher Site | Google Scholar
  55. L. Lin, X. Jiang, Z. Zhang et al., “Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection,” Gut, vol. 69, no. 6, pp. 997–1001, 2020. View at: Publisher Site | Google Scholar

Copyright © 2021 Mohammad Pourfridoni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.